Multiple Myeloma: Impact of Time to Transplant on the Outcome.

Background: Autologous stem cell transplant (ASCT) is a standard therapy for transplant eligible patients of multiple myeloma (MM). To evaluate impact of time to transplant on subsequent outcomes, we analyzed data on consecutive MM patients who received novel agents-based induction prior to transplant.

Methods: Between 2006 and 2019, 363 MM patients underwent ASCT.